|
|
Article: Rhone-Poulenc Rorer Launches a Room-Temperature Formulation of DDAVP(R) Nasal Spray for Treatment of Primary Nocturnal Enuresis
- Article from:
- PR Newswire
- Article date:
- July 14, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Formulation Offers Convenience to Families With Children Who Wet the Bed
COLLEGEVILLE, Pa., July 14 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) today announced that a new room-temperature formulation of DDAVP (desmopressin acetate) Nasal Spray is now available in the United States for the treatment of primary nocturnal enuresis (PNE), commonly known as bed-wetting.
"Room temperature DDAVP may offer convenience to those patients who are required to administer the medication in environments outside the home, such as summer camp or Boy- or Girl-Scout overnights," said Yurii Reinberg, MD, a pediatric urologist in Minneapolis. "Because the ...